Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: a real-world analysis. - Kao CH; Lin H; Ou YC; Fu HC; Tsai CC; Wu CH (Frontiers in immunology, 2026)